ATE502030T1 - Imidazolderivate, verfahren zu deren herstellung und deren verwendung - Google Patents

Imidazolderivate, verfahren zu deren herstellung und deren verwendung

Info

Publication number
ATE502030T1
ATE502030T1 AT01982839T AT01982839T ATE502030T1 AT E502030 T1 ATE502030 T1 AT E502030T1 AT 01982839 T AT01982839 T AT 01982839T AT 01982839 T AT01982839 T AT 01982839T AT E502030 T1 ATE502030 T1 AT E502030T1
Authority
AT
Austria
Prior art keywords
ring
chem
production
alkyl group
membered
Prior art date
Application number
AT01982839T
Other languages
English (en)
Inventor
Akihiro Tasaka
Nobuyuki Matsunaga
Akio Ojida
Masami Kusaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE502030T1 publication Critical patent/ATE502030T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01982839T 2000-11-20 2001-11-19 Imidazolderivate, verfahren zu deren herstellung und deren verwendung ATE502030T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000353634 2000-11-20
JP2000382056 2000-12-15
PCT/JP2001/010079 WO2002040470A1 (en) 2000-11-20 2001-11-19 Imidazole derivatives, process for their preparation and their use

Publications (1)

Publication Number Publication Date
ATE502030T1 true ATE502030T1 (de) 2011-04-15

Family

ID=26604319

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982839T ATE502030T1 (de) 2000-11-20 2001-11-19 Imidazolderivate, verfahren zu deren herstellung und deren verwendung

Country Status (7)

Country Link
US (1) US6960586B2 (de)
EP (1) EP1344777B1 (de)
AT (1) ATE502030T1 (de)
AU (1) AU2002214320A1 (de)
CA (1) CA2429437A1 (de)
DE (1) DE60144246D1 (de)
WO (1) WO2002040470A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
EP1830845A2 (de) * 2004-11-09 2007-09-12 Shering Corporation Verbessertes dosierschema von temozolomid zur behandlung von krebs auf grundlage des mgmt-spiegels eines patienten
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
JP2009541219A (ja) * 2006-06-12 2009-11-26 メルク エンド カムパニー インコーポレーテッド 高眼圧治療のための眼科組成物
CA2686848A1 (en) * 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
US8180029B2 (en) 2007-06-28 2012-05-15 Voxer Ip Llc Telecommunication and multimedia management method and apparatus
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
KR102888073B1 (ko) * 2021-03-19 2025-11-19 호쿠에츠 코포레이션 가부시키가이샤 전자파 노이즈 억제 시트 및 그 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
ZA882717B (en) 1987-04-22 1988-10-17 Merrell Dow Pharmaceuticals Inc. 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
WO1992015604A1 (en) 1991-02-27 1992-09-17 New York University Anti-testosterone compounds and method of use thereof
CA2104234A1 (en) 1991-03-01 1993-07-22 Denis R. Mckay Powder coating method for producing circuit board laminae and the like
US5457102A (en) 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
CA2132449C (en) 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
WO1995009157A1 (en) 1993-09-30 1995-04-06 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
AU3846395A (en) 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
WO1997000257A1 (en) 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
WO1998037070A1 (en) 1997-02-21 1998-08-27 Takeda Chemical Industries, Ltd. Fused ring compounds, process for producing the same and use thereof
DE69823222T2 (de) 1997-10-02 2005-04-14 Daiichi Pharmaceutical Co., Ltd. Dihydronaphthalinderivate und verfahren zur herstellung derselben
EP1073640B1 (de) 1998-04-23 2005-04-13 Takeda Pharmaceutical Company Limited Naphthalene derivate ,ihre herstellung und verwendung
AU7950100A (en) * 1999-10-22 2001-05-08 Takeda Chemical Industries Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
WO2001030763A1 (en) * 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. Process for producing optically active naphthalene derivative and optical resolver therefor

Also Published As

Publication number Publication date
CA2429437A1 (en) 2002-05-23
US20040024039A1 (en) 2004-02-05
EP1344777A1 (de) 2003-09-17
EP1344777A4 (de) 2007-05-09
AU2002214320A1 (en) 2002-05-27
US6960586B2 (en) 2005-11-01
EP1344777B1 (de) 2011-03-16
WO2002040470A1 (en) 2002-05-23
DE60144246D1 (de) 2011-04-28

Similar Documents

Publication Publication Date Title
ATE440096T1 (de) Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung
NZ532494A (en) Dibenzylamine compound and medicinal use thereof
DE60226912D1 (de) Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
CY1117132T1 (el) Παραγωγο θειαζολιου
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
DE602004024880D1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
KR960701878A (ko) 수용성 캄프토테신 유도체, 이의 제조 방법 및 항종양제로서의 이의 용도(Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents)
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
DE69406323D1 (de) Substituierte Aminsäure Derivate verwendbar für die Behandlung von Arteriosclerosis
ATE178056T1 (de) Substituierte tertiäre amine und deren salze
DK1847534T3 (da) Thiadiazolin-derivater til behandling af kræft
ATE502030T1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
ATE321552T1 (de) 1-substituierte-phenyl-1-(1h-imidazol-4- yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
DE3867899D1 (de) Verfahren zur herstellung von 4-amino-androstendion-derivaten.
ATE504572T1 (de) Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
DE60000978D1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
ES2111086T3 (es) Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos.
DE69725167D1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties